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ABSTRACT
In abstinent alcoholics, stress induces negative affect—a re-
sponse linked to craving and relapse. In rats, repeated stresses at
weekly intervals before 5-day ethanol diet sensitize withdrawal-
induced anxiety-like behavior (“anxiety”) that is blocked by a cor-
ticotrophin-releasing factor 1 (CRF-1)-receptor antagonist. Cur-
rent experiments were performed to identify brain sites that
support CRF involvement in stress sensitization of ethanol with-
drawal-induced anxiety-like behavior. First, different doses of CRF
microinjected weekly into the central amygdala (CeA) before eth-
anol exposure produced a dose-related sensitization of anxiety
during ethanol withdrawal. Subsequently, CRF microinjection into
the basolateral amygdala, dorsal raphe nucleus (DRN), or dorsal
bed nucleus of the stria terminalis (d-BNST) also sensitized etha-
nol withdrawal-induced anxiety. In contrast, sensitization of etha-
nol withdrawal-induced anxiety was not observed after weekly
CRF administration into the ventral-BNST, CA1-hippocampal re-
gion, or hypothalamic-paraventricular nucleus. Then, experi-
ments documented the CRF receptor subtype responsible for
CRF and stress sensitization of withdrawal-induced anxiety.
Systemic administration of a CRF-1 receptor antagonist before
CRF microinjection into the CeA, DRN, or d-BNST prevented
CRF-induced sensitization of anxiety during ethanol with-
drawal. Furthermore, repeated microinjections of urocortin-3, a
CRF-2 receptor agonist, into the CRF-positive sites did not
sensitize anxiety after withdrawal from ethanol. Finally, micro-
injection of a CRF-1 receptor antagonist into the CeA, DRN, or
d-BNST before stress blocked sensitization of anxiety-like be-
havior induced by the repeated stress/ethanol withdrawal pro-
tocol. These results indicate that CRF released by stress acts
on CRF-1 receptors within specific brain regions to produce a
cumulative adaptation that sensitizes anxiety-like behavior dur-
ing withdrawal from chronic ethanol exposure.
Considerable evidence supports involvement of corticotro-
phin-releasing factor (CRF), a 41-amino-acid peptide (Vale et
al., 1981), in stress (Koob and Heinrichs, 1999; Bale and
Vale, 2004), in production of anxiety (Spina et al., 2002), and
in the expression of anxiety-like behavior (“anxiety”) during
withdrawal from chronic ethanol (Baldwin et al., 1991; Over-
street et al., 2004). Previous work demonstrated that re-
peated stresses before the 5-day chronic ethanol diet (stress/
withdrawal protocol) sensitized anxiety during withdrawal
(Breese et al., 2004). Subsequently, a CRF-1 receptor antag-
onist prevented this sensitization (Breese et al., 2004),
whereas repeated intracerebroventricular administrations of
CRF before ethanol exposure substituted for stress to induce
sensitization (Overstreet et al., 2004). Because it has been
shown that corticosterone induced by CRF activation of the
hypothalamic pituitary adrenal axis was not responsible for the
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stress/withdrawal-induced sensitization (Breese et al., 2004),
these efforts provided critical support for an extrahypothalamic
action of CRF being responsible for the sensitization.
An important aspect not previously explored is the neuro-
anatomical basis of CRF involvement in repeated stress sen-
sitization. CRF (Cummings et al., 1983; Swanson et al., 1983)
and CRF receptors (De Souza et al., 1985) are localized to
regions of the extended amygdala (Alheid, 2003), sites that
are reportedly related to anxiety-like behavior (Koob, 2008).
Therefore, it was reasoned that sites that support CRF-in-
duced sensitization could be identified by repeatedly micro-
injecting CRF into appropriate brain sites before chronic
ethanol exposure. Furthermore, by administering a CRF-1
receptor antagonist into CRF-positive brain regions the role
of CRF in repeated stress/withdrawal protocol sensitization
of anxiety (Breese et al., 2004) could be confirmed.
Several brain regions known to be associated with anxiety-
like behavior, including the central nucleus of the amygdala
(CeA), the basolateral amygdala (BLA), the dorsal raphe
nucleus (DRN), and the bed nucleus of the stria terminalis
(BNST) contain CRF (Cummings et al., 1983; Swanson et al.,
1983) and CRF receptors (De Souza et al., 1985; Van Pett
et al., 2000). Because microinjection of a general CRF recep-
tor antagonist into the CeA reversed the anxiogenic response
to acute ethanol withdrawal (Baldwin et al., 1991; Rassnick
et al., 1993), this site was the first to be chosen for investi-
gation. The DRN was chosen because this site has been
shown to have an association with sensitization of anxiety
induced by repeated withdrawals (Overstreet et al., 2006).
The BNST was chosen because it is linked to the amygdala
(Dong et al., 2001) and has an association with fear- and anxi-
ety-associated behaviors (Davis et al., 1997; Sahuque et al.,
2006; Lee et al., 2008). In addition to these brain sites, the
paraventricular nucleus (PVN) of the hypothalamus and
the CA1 region of the hippocampus were tested with CRF.
The PVN is a critical brain site for control of the hypotha-
lamic pituitary adrenal axis (Rivier et al., 1983) and also
contains CRF (Swanson et al., 1983) and CRF receptors (De
Souza et al., 1985; Van Pett et al., 2000), but has not been
associated with anxiety-like behavior. The CA1-hippocampal
region was chosen because it has neural interactions with the
amygdala (Akirav and Richter-Levin, 1999; Sheth et al.,
2008) and there are CRF receptors present at this site (De
Souza et al., 1985; Van Pett et al., 2000).
Even though CRF reportedly has approximately a 17-fold
greater affinity for CRF-1 receptors than CRF-2 receptors
(Vaughan et al., 1995; Hauger et al., 2003), we sought to
confirm previous evidence for CRF-1 receptor involvement in
the CRF/withdrawal (Overstreet et al., 2004) and stress/
withdrawal (Breese et al., 2004) protocols. Testing for in-
volvement of specific CRF-receptor subtypes in sensitization
of withdrawal-induced anxiety was identified by administer-
ing a CRF-1 receptor antagonist systemically before repeated
CRF microinjection or by substituting urocortin-3, a CRF-2
receptor agonist (Lewis et al., 2001), for CRF microinjection
into selected brain sites before the 5 days of ethanol diet.
Urocortin-3 has virtually no effect on CRF-1 receptors. In
addition, to confirm the involvement of CRF-1 receptors in
stress sensitization of withdrawal-induced anxiety (Breese et
al., 2004), a CRF1-receptor antagonist was administered be-
fore each repeated stress application into sites where micro-
injected CRF was found to sensitize ethanol withdrawal-
induced anxiety-like behavior.
Collectively, the present investigations sought to extend
our understanding of the neuroanatomical basis of CRF in-
volvement in the repeated stress sensitization of ethanol
withdrawal-induced anxiety and document the CRF receptor
subtype linked to this sensitization. In addition, these data
were expected to confirm that stress and CRF induce a cu-
mulative maladaptation that is made apparent only when
followed by ethanol exposure and withdrawal.
Materials and Methods
Animals. Male Sprague-Dawley rats (Charles River Laboratories,
Wilmington, MA, or Harlan, Indianapolis, IN) weighing 180 to 200 g
were housed in groups of three or four for several days to acclimate
to the local conditions (at 22°C and 40% humidity; dark/light cycle of
12:12 with lights on at 7:00 AM and off at 7:00 PM). After acclima-
tion, the rats underwent surgery as described below. After surgery
the animals were individually housed and, after several days of
recovery, were placed on a nutritionally complete lactalbumin-dex-
trose diet and ultimately microinjected centrally as per the strate-
gies outlined. All procedures for the animals were approved by the
Institutional Animal Care and Use Committee at the University of
North Carolina at Chapel Hill.
Surgery for Cannula Implantation. Surgery to implant stain-
less steel cannulae into brain sites was performed under 2.5% isoflu-
rane anesthesia. While anesthetized, a rat was placed in a stereo-
taxic frame (David Kopf Instruments, Tujunga, CA). The dorsal
surface of the skull was exposed, and holes were drilled over the
appropriate region for placement of the cannulae. The cannulae
(26-gauge stainless steel tubing) were directed dorsal to the brain
site being microinjected with use of coordinates from a rat atlas
(Paxinos and Watson, 2005). The rats received bilateral cannula
implants over the CeA (AP  2.3, ML  4.5, DV  5.5), BLA
(AP  2.3, ML  5, DV  6), the CA1 region of the hippocampus
(AP  4, ML  3, DV 1.5) , and either the dorsal (AP  0.24,
ML  1.6, DV  2) or the ventral (AP  4, ML  3, DV 
1.5) BNST. In addition, unilateral cannulae were implanted above
the lateral ventricle for the intracerebroventricular injections (AP 
0.8, ML  1.6, DV  2). Because the DRN (AP  1.56 from
lambda, ML  3.5, DV  4.94) and the PVN of the hypothalamus
(AP  1.88, ML  3, DV  6.5) are midline structures, bilateral
injections were not needed. All injections were angled to these mid-
line locations from the drill holes on the right side of the skull.
Insertion angles were 30° for the DRN and 20.7° for the PVN. The
distances from the cannula tips to the injection sites were as follows:
CeA, 2.5 mm; BLA, 2.5 mm; DRN, 2 mm; d-BNST, 4.5 mm; v-BNST,
4.5 mm; hippocampus, 2 mm; PVN, 2.05 mm; intracerebroventricu-
lar, 2.5 mm. Targeted brain sites and limits for acceptance of data
are discussed below. Cannulae were secured to the skull with stain-
less steel screws and acrylic dental cement (Frye et al., 1983; Over-
street et al., 2006; Knapp et al., 2007). Once recovered from surgery,
the rats were given acetaminophen (Children’s Q-PAP, cherry fla-
vored, 6 mg/ml) in the drinking water for 48 h. The rats were allowed
to recover for at least 3 days before proceeding with further experi-
mental procedures.
Procedures for Diet Administration. After the recovery pe-
riod, the rats were given a nutritionally complete control liquid diet
(Frye et al., 1983; Overstreet et al., 2002). Rats received a calorically
balanced and nutritionally complete control liquid diet for 12 days
and were then placed on either a similar liquid diet containing 4.5%
ethanol for 5 days or continued receiving the control diet (Overstreet
et al., 2002). Rats were weighed at weekly intervals, and volumes of
diet were adjusted to ensure that groups within a given investigation
gained weight similarly. Previous reports (Overstreet et al., 2002;
Breese et al., 2004) have demonstrated that this exposure to 4.5%
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ethanol diet produces blood ethanol levels of approximately 80 to 110
mg% before removal. The ethanol is reduced to near 0 by 5 to 6 h
(Overstreet et al., 2002; Breese et al., 2004)—the time at which
behaviors related to social interaction are monitored (see below).
Procedures for Microinjection of CRF and Urocortin-3 into
Selected Brain Regions on Sensitization of Ethanol With-
drawal-Induced Anxiety. Our laboratory prepares animals rou-
tinely for microinjection (Frye et al., 1983; Overstreet et al., 2006;
Knapp et al., 2007). While on a liquid diet containing no ethanol, rats
received microinjections of CRF (0.045–0.5 g/0.5 l per site) and
urocortin-3 (0.5 g/0.5 l per site or 5 g/5 l i.c.v.) or vehicle (as
appropriate) into the selected brain regions on days 6 and 12 in a
temporal sequence comparable with that used with the repeated-
stress exposure protocol (Breese et al., 2004). The general protocol
for treatment is illustrated in Fig. 1. CRF was administered into the
CeA, BLA, DRN, d-BNST, v-BNST, CA1 of the hippocampus, or the
PVN of the hypothalamus. Urocortin-3 was microinjected intracere-
broventricularly or into the CeA, DRN, and d-BNST. The doses of
CRF and urocortin-3 were dissolved in an artificial cerebrospinal
fluid (aCSF) and delivered into each brain site through 32-gauge
injectors placed into the implanted cannula guides. During place-
ment of the injector needle into a given brain site, the animals were
gently restrained in a cotton towel. The maximal dose of CRF was
administered weekly into the CeA before 5 days of control diet to
demonstrate a lack of effect of this treatment on social interaction. A
1-l syringe delivered the 0.5 l of the drug solution into each of the
brain sites (per side, if bilateral). In addition, a urocortin-3 dose (5
g/5 l i.c.v.) was administered into the ventricular cannula over a
1-min period by use of a 5-l syringe. Urocortin-3 is active on CRF-2
receptors with virtually no affinity for CRF1 receptors (Lewis et al.,
2001). The injector remained in place for 1 min after the end of the
infusion. Five days of 4.5% ethanol diet was initiated 24 h after
microinjection of CRF or urocortin-3 followed by determination of
social interaction behavior during withdrawal from the ethanol as
noted below.
Testing of a CRF-1 Receptor Antagonist on CRF Sensitiza-
tion of Ethanol Withdrawal-Induced Anxiety. The CRF-1 recep-
tor antagonist SSR125543 (10 mg/kg i.p.; sanofi-aventis, Bridgewa-
ter, NJ) (Griebel et al., 2002) or CP-154,526 (10 mg/kg i.p.; Tocris
Bioscience, Ellisville, MO) (Schulz et al., 1996) was prepared as a
suspension in 0.5% carboxymethylcellulose and 2.5% Tween 80. Both
antagonists were used to confirm a blockade of CRF action. The
CRF-1 receptor antagonist or the corresponding vehicle was given
intraperitoneally 15 min before each of the repeated microinjections
of CRF (0.5 g in 0.5 l prepared in aCSF) into designated brain
sites. The 5 days of 4.5% ethanol diet started on day 13 as outlined
in Fig. 1. Social interaction was measured between 5 and 6 h of
withdrawal from the ethanol diet as noted below.
Testing of a CRF-1 Receptor Antagonist into Selected Brain
Sites on Stress Sensitization of Ethanol Withdrawal-Induced
Anxiety. To test CRF involvement in the CeA, DRN, or d-BNST in
the sensitization of ethanol withdrawal-induced anxiety elicited by
the stress/withdrawal protocol (Breese et al., 2004), rats were treated
with either the CRF1-receptor antagonist SSR125543 (10 g/0.5 l)
or vehicle in each brain site 15 min before each stress session during
exposure to the control liquid diet. The SSR125543 was dissolved in
the aCSF containing 2.5% Tween 80. The stress sessions consisted of
restraining rats in plastic conical decapicones for 60 min on days 6
and 12. Either a single 5-day cycle of 4.5% ethanol diet was initiated
24 h after the final stress or the control diet was continued (Breese
et al., 2004). Social interaction changes were measured during with-
drawal from ethanol diet as noted below.
Social Interaction Test. The social interaction test was given
5 h after the ethanol diet was withdrawn—a time at which the
ethanol levels reach zero (Overstreet et al., 2002; Breese et al., 2004).
In contrast to the original testing method of File (1980) that empha-
sized the score of the rat pair (see review by File and Seth, 2003), the
social interaction measure for this investigation used the behavior of
each rat in the pair, as established previously (Overstreet et al.,
2002, 2003). For testing, each rat was placed in a test box (65  65
cm with 47-cm walls) with an unfamiliar test partner for 5 min to
evaluate social interaction (Overstreet et al., 2002). An observer
blind to treatments scored the time rats spent in active social con-
tact. Behaviors monitored included sniffing, nipping, grooming,
mounting, kicking, wrestling, jumping on, and crawling under or
over the partner (Overstreet et al., 2002; File and Seth, 2003). A
locomotor activity score was also obtained based on crossings over a
grid (Overstreet et al., 2002).
Histological Confirmation of Injection Sites. To confirm ap-
propriate placement, the cannula sites were defined histologically at
the end of each experimental series. In this case, 0.5 l of methyl
green dye was microinjected into the brain site as described by





























A  Repeated CRF, Urocortin3 or Stresses 







Fig. 1. Protocol for repeated administration of CRF, urocortin 3, or repeated stresses before 5 days of chronic ED to assess for deficits in social
interaction: drug treatments. A, at the arrows on days 6 and 12, CRF or urocortin 3 was microinjected weekly into selected brain regions or 60 min
of restraint stress was applied followed by 5 days of 4.5% ethanol liquid diet. For these experiments, some groups received control diet for the entire
study period and were given either CRF, urocortin 3, or vehicle. A group received vehicle (i.e., no other treatment) before the ethanol diet. Social
interaction, a test of anxiety-like behavior, was measured 5 to 6 h after removal of the ethanol diet exposure. B, as a further approach to investigate
the role of CRF receptor subtype involved in the repeated CRF or stress-induced sensitization of ethanol withdrawal anxiety-like behavior, a CRF-1
receptor (CRF-1R) antagonist was administered intraperitoneally 15 min before the microinjection of CRF or was microinjected into each of the
CRF-positive sites 15 min before the application of restraint stress on days 6 and 12. As noted for A, some groups of rats received only control diet that
had vehicle microinjected or vehicle applied before stress. Likewise, a group that received only 5 days of ethanol diet received vehicle. Social interaction
test was conducted 5 to 6 h after removal of the ethanol diet exposures.
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Knapp et al. (2007) with use of the same injectors used to microinject
CRF, urocortin-3, and the CRF-1 receptor antagonist. After eutha-
nizing the rat, the brain was removed, frozen on dry ice, and stored
at 80°C until sections were cut on a microtome to confirm the site
of injection by an individual blind to the treatments. To provide a
representation of placement of microinjections, Supplemental Mate-
rial is provided noting the limits for acceptance. Figure 3 demon-
strates specific injection sites for CRF identified in the CeA. Only
animals with the correct cannula locations were used in the statis-
tical analysis. In general, proper cannula placement was between
80% and 90%.
Statistics. The measures obtained from the testing of anxiety
(seconds of social interaction), locomotor test (crossings), ethanol
intake, and body weight were analyzed with analysis of variance
followed by Fisher’s protected least significant difference tests for
comparisons of individual groups within an investigation. When data
for differing brain sites for either the CD-vehicle or the ED-vehicle
groups were combined (see Figs. 4, 5, and 8), no significant difference
was observed in social interaction across the different brain regions
for CD vehicle [F(5,61)  0.748; P  0.1] and for ED vehicle
[F(5,66)  0.696; P  0.1]. Therefore, vehicle data for either the
CD-vehicle group or the ED-vehicle group from data sets that con-
tained results from different brain sites were combined for the indi-
vidual experimental illustrations (figures).
Results
CRF Dose Effect in the CeA on Sensitization of Eth-
anol Withdrawal-Induced Anxiety. Repeated microinjec-
tions of CRF into the CeA before 5 days of ethanol diet were
used to assess the potential action of this peptide within this
site to sensitize ethanol withdrawal-induced anxiety. As
shown in Fig. 2, the repeated CRF microinjections into the
CeA reduced social interaction in a dose-related fashion in-
dicating that the CeA can support the action of CRF to induce
sensitization of withdrawal-induced anxiety. The location of
the injection sites for the 0.5-g CRF dose administered in
the CeA is illustrated (Fig. 3).
Consistent with early studies of intracerebroventricular
injections of CRF (Overstreet et al., 2004), two 0.5-g doses of
CRF, which produced a maximal effect on social interaction
when administered before ethanol (Fig. 1), did not alter social
interaction when microinjected into the CeA before 5 days of
control diet (CD-CRF). Because the lowest dose of CRF was
without effect in alcohol-exposed rats, it would unlikely that
lower doses would have an action in controls. Likewise, re-
peated vehicle microinjections before the 5 days of ethanol
diet were without effect (ED vehicle). These findings collec-
tively demonstrate the need for the weekly doses of CRF to be
given in combination with ethanol diet to produce the reflec-
tion of adaptive change (i.e., a reduction in social interac-







































Fig. 2. Repeated administration of CRF into the CeA before ethanol diet
reduces social interaction behaviors during withdrawal from chronic eth-
anol: dose-effect relationship. CRF (0.045 g, 0.15 g, or 0.5 g) was
given twice at weekly intervals into the CeA before exposure to 5 days of
4.5% ED (see Fig. 1 for illustration of the protocol). A representation of
the sites at which CRF (0.5 g) was administered into the CeA is pre-
sented in Fig. 3. Social interaction, as a measure of anxiety-like behavior,
was measured 5 to 6 h after ethanol diet removal. No effect on social
interaction was observed during ethanol withdrawal in rats that received
only 5 days of 4.5% ethanol diet with vehicle injections (ED vehicle) or
that received the two injections of CRF (0.5 g) into the CeA while
animals were consuming CD. The number of rats in each group is pro-
vided in Table 1, part 1. , Significantly different from CD-vehicle, CD-
CRF, and ED-vehicle groups [F(5,41)  7.278, P  0.001].
Fig. 3. Representative dye spots derived from
post-mortem histological assessments of 0.5-l in-
jections for the 0.5-g CRF injections into the CeA.
The image is adapted from Paxinos and Watson
(2005). The hatched lines represent approximate
limits of injection variability deemed acceptable.
The dots represent the estimated centers of dye
spots found upon histological examination. See
Materials and Methods for the targeted coordi-
nates for this region. The other brain sites of focus
are included in the Supplemental Material.
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showed that social interaction scores for vehicle are equiva-
lent to values in rats that do not receive central microinjec-
tions (Overstreet et al., 2002; Breese et al., 2004), unpub-
lished work showed that the social interaction score for CD
vehicle was not different from that of rats that receive no
surgery or vehicle. However, when results for the ED-CRF
groups are compared with the social interaction score ob-
tained with the repeated CRF dosing alone before control diet
(CD-CRF) or the ethanol diet alone (ED vehicle), it is appar-
ent that the combination of CRF and ethanol is required for
induction of sensitization of withdrawal-induced anxiety.
The first part of Table 1 indicates the number of rats in each
group for Fig. 2 and demonstrates that measures for locomo-
tor activity, body weight, and alcohol intake for groups did
not differ.
Repeated CRF Microinjections into the BLA, DRN,
or d-BNST Sensitize Ethanol Withdrawal-Induced
Anxiety. To evaluate whether CRF would induce sensitiza-
tion when microinjected into other brain sites that contained
CRF receptors (De Souza et al., 1985; Van Pett et al., 2000)
and that have been associated with anxiety-like behaviors
(Davis et al., 1997; Overstreet et al., 2006; Lee et al., 2008),
CRF was microinjected into the BLA, DRN, and d-BNST. As
shown in Fig. 4, a 0.5-g CRF dose repeatedly microinjected
into either the BLA, the DRN, or the d-BNST at a weekly
interval before 5 days of ethanol diet decreased social inter-
action during ethanol withdrawal—a response indicative of
enhanced anxiety-like behavior. Thus, just as seen when
CRF was microinjected into the CeA (Fig. 2), CRF injected
into each of these additional brain sites also decreased social
interaction during ethanol withdrawal. See Supplemental
Data for additional information on these sites.
Figure 4 also demonstrates that microinjection of vehicle
into the selected brain sites before ethanol diet (ED vehicle)
or in the control diet controls (CD vehicle) was without effect
on social interaction (see Materials and Methods for details).
Because repeated intracerebroventricular administration of
CRF (Overstreet et al., 2004) and repeated administration of
CRF into the CeA (Fig. 2) before control diet did not sensitize
ethanol withdrawal-induced anxiety, the repeated CRF ad-
ministration into all of the brain sites before control diet was
not deemed necessary. See Table 1, part 2, for the numbers of
rats in each group and data illustrating that treatments had
no significant effect on locomotion during testing and show-
ing the equal weight gain for these groups.
Repeated CRF Microinjections into the PVN of the
Hypothalamus, v-BNST, or the CA1 Region of the Hip-
pocampus Do Not Sensitize Ethanol Withdrawal-In-
duced Anxiety. In addition to the brain regions described
above, CRF (0.5 g) action on sensitization of ethanol with-
drawal-induced anxiety was investigated in other brain ar-
eas. Because the BNST has two distinct regions (Egli and
Winder, 2003), CRF was repeatedly microinjected into the
v-BNST before administration of 5 days of ethanol diet. The
other brain regions included the PVN of the hypothalamus and
the CA1 region of the hippocampus. Apparent from Fig. 5 and
in contrast to the brain regions described previously (Figs. 2
and 4), the repeated CRF microinjections into these brain
sites (i.e., PVN, v-BNST, and CA1) before the 5 days of 4.5%
ethanol diet did not reduce social interaction during with-
drawal from the 5-day single cycle of ethanol diet compared
with the groups that received vehicle into sites—a reflection
of a lack of sensitization of ethanol withdrawal-induced anx-
iety-like behavior by CRF in these brain regions. See Sup-
plementary Data for further information on these sites. As
before, alcohol intake, body weight, and locomotor activity for
groups did not differ (Table 1, part 3).
TABLE 1
Ethanol intakes, body weights, and locomotor activity for groups in
Figs. 2 and 4 through 8






g/kg/day g crosses/5 min
1. CRF Dose Response on Social Interaction (Fig. 2)
CD Veh (7) – 336  5 112  8
CD CRF-0.5 (9) – 324  6 131  7
ED Veh (7) 7.42  0.24 328  5 99  7
ED CRF-0.045 (8) 7.87  0.14 328  6 100  10
ED CRF-0.15 (8) 7.70  0.19 331  6 113  13
ED CRF-0.5 (8) 7.76  0.18 330  7 96  10
NS NS NS
2. CRF Microinjections into the BLA, DRN, and d-BNST on Social
Interaction (Fig. 4)
CD Veh (12) – 320  9 88  15
ED Veh (10) 7.08  0.20 341  5 83  18
ED BLA CRF (7) 7.53  0.06 330  4 97  7
ED DRN CRF (8) 7.36  0.36 325  8 69  8
ED d-BNST CRF (10) 7.23  0.27 302  6 63  7
NS NS NS
3. CRF Microinjections into the v-BNST, PVN, and CA1-Hippocampus
on Social Interaction (Fig. 5)
CD Veh (9) – 312  11 95  20
ED Veh (10) 7.56  0.49 325  6 92  15
ED V BNST CRF (8) 8.56  0.18 304  12 72  10
ED PVN CRF (9) 8.45  0.21 292  10 90  12
ED Hippo CRF (9) 8.17  0.18 340  7 72  10
NS NS NS
4. CRF-Induced Sensitization of Anxiety Blockade by CRF-1 Receptor
Antagonists (Fig. 6)
CD Veh (13) – 315  9 91  14
ED Veh (22) 7.47  0.17 333  7 94  10
ED CeA CRF (9) 6.91  0.24 321  10 89  12
ED SSR i.p. CeA CRF (8) 8.35  0.22 317  7 119  11
ED DRN CRF (8) 8.52  0.20 306  8 94  10
ED CP i.p. DRN CRF (8) 7.75  0.19 315  9 81  13
ED d-BNST CRF (8) 7.32  0.14 312  11 77  16
ED SSR i.p. d-BNST
CRF (8)
7.24  0.26 326  5 80  12
NS NS NS
5. Urocortin-3 into CeA, DRN, and d-BNST on Social Interaction
(Fig. 7)
CD Veh (8) – 306  4 119  10
CD UCN-3 (8) – 319  5 121  10
ED Veh (14) 7.37  0.18 323  5 111  8
ED CeA UCN-3 (8) 7.97  0.28 327  5 109  4
ED DRN UCN-3 (11) 7.60  0.26 328  8 102  8
ED d-BNST UCN-3 (8) 7.60  0.20 306  11 122  7
ED i.c.v. UCN-3 (9) 7.90  0.18 304  9 116  7
NS NS NS
6. Blockade of Stress Sensitization by CRF-1 Antagonist into the CeA,
DRN, or d-BNST (Fig. 8)
CD Veh (18) – 310  7 127  10
CD Stress (10) – 298  6 132  10
ED Veh (9) 7.57  0.32 314  9 112  17
ED Stress Veh CeA (7) 8.24  0.19 295  8 111  16
ED Stress SSR CeA (8) 8.26  0.21 303  6 135  16
ED Stress Veh DRN (8) 7.70  0.30 312  8 132  11
ED Stress SSR DRN (11) 8.20  0.25 309  11 129  13
ED Stress Veh
d-BNST (6)
8.01  0.24 300  12 130  12
ED Stress SSR
d-BNST (7)
8.33  0.24 285  7 129  6
NS NS NS
N.S., no significant difference noted among the groups for any of the measures for
each of the six experiments (1–6); Hippo, hippocampus; Veh, vehicle; SSR,
SSR125543.
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Systemic Administration of CRF-1 Receptor Antago-
nists Prevents Microinjected CRF-Induced Sensitiza-
tion of Withdrawal-Induced Anxiety from the CeA,
DRN, and d-BNST. Previous work has demonstrated that
CRF has greater affinity for and more functional activity
from CRF-1 receptors than from CRF-2 receptors (Vaughan
et al., 1995; Hauger et al., 2003). To address whether CRF-1
receptors, but not CRF-2 receptors, were involved in the
CRF-induced sensitization of ethanol withdrawal-induced
anxiety-like behavior from the CeA, DRN, and d-BNST,
CRF-1 receptor antagonists were given 15 min before each of
the CRF microinjections. The CRF-1 receptor antagonist
SSR125543 (10 mg/kg i.p.; Griebel et al., 2002) was given
before each of the CRF microinjections into the CeA and
d-BNST. In addition, CP154526 (10 mg/kg i.p.; Schulz et al.,
1996) was administered before each of the CRF microinjec-
tions into the DRN to confirm that a different CRF-1 receptor
antagonist would have an effect similar to the SSR125543 in
another CRF-sensitive brain site. Results confirm that CRF
into each of these brain sites sensitizes ethanol withdrawal-
induced anxiety as shown in Figs. 2 and 4. In each of the
cases, this action of CRF to induce sensitization of ethanol
withdrawal-induced anxiety was prevented by the CRF-1
receptor antagonists (Fig. 6). These findings are consistent
with CRF action on CRF-1 receptors being critical to the sensi-
tization induced from these brain sites. As before, locomotor
activity, body weight, and alcohol intake were not significantly
affected by any of these treatments (Table 1, part 4).
Lack of Effect of Urocortin-3 on Sensitization of Eth-
anol Withdrawal-Induced Anxiety. To confirm the con-
clusion that CRF-1, but not CRF-2 receptors, were critical to
the action of repeated CRF administration before ethanol
diet, we tested whether repeated microinjections of a dose of
the CRF-2 receptor agonist, urocortin-3 (UCN-3) (Lewis et
al., 2001) equivalent to that of the highest dose of CRF
administered into the CeA (Fig. 2), the DRN, or the d-BNST
would, like CRF, sensitize ethanol withdrawal-induced anx-
iety-like behavior. Urocortin-3 has virtually no measurable
effect on the CRF-1 receptor (Lewis et al., 2001). As shown in
Fig. 7, this dose of UCN-3 was without a significant effect
when microinjected into these brain sites that supported the
action of CRF. Finally, to rule out the possibility that UCN-3
might have an effect in other brain sites than those that
support the CRF sensitization, UCN-3 was repeatedly in-
jected intracerebroventricularly before the 5-day ethanol ex-
posure. Again, UCN-3 showed no effect on sensitization of
ethanol withdrawal-induced anxiety. These findings pro-
vided further evidence for CRF-1 receptors being critical to
the action of CRF to sensitize ethanol withdrawal-induced
anxiety from the CeA, DRN, and the d-BNST. Locomotor
activity, body weight, and alcohol intake were not signifi-
cantly different for any of the treatments (Table 1, part 5).
CRF-1 Receptor Antagonist Blocks Anxiogenic Ef-
fect of Stress after Microinjection into the CeA, DRN,
or the d-BNST. Breese et al. (2004) showed that two appli-
cations of 60-min restraint stresses at weekly intervals pre-






































Fig. 4. Repeated CRF into the BLA, DRN, and d-BNST before ethanol
diet reduces social interaction behaviors during withdrawal from chronic
ethanol. The CRF dose (0.5 g/0.5 l) was microinjected twice at weekly
intervals into the BLA, DRN, or d-BNST before exposure to 5 days of 4.5%
ED (see Fig. 1 for protocol). A representation of the site and limits at
which CRF was administered into each of these brain sites is presented
in supplementary material. In the CD-vehicle and ED-vehicle groups,
vehicle was administered into each of the brain sites (n  3–4 for each
site) and data for these vehicle injections were combined because a
significant change across sites was not observed for these groups. When
social interaction for the CD-vehicle group was compared with the ED-
vehicle group, no significant effect was observed (P  0.05). A group that
received CRF and was on control diet only was not included for each of the
present sites because previous data demonstrated that intracerebroven-
tricular administration of CRF to rats that received control diet does not
induce sensitization (Overstreet et al., 2004) and the repeated CRF in the
CeA of control diet-treated animals likewise did not sensitize withdrawal-
induced anxiety (Fig. 2). Social interaction was measured 5 to 6 h after
the ethanol diet removal. The number of rats for each group is listed in
Table 1, part 2. Representative sites where CRF was microinjected are
presented in Supplemental Material. , Significantly different from CD-



































Fig. 5. Absence of effect of repeated CRF microinjections into the PVN,
v-BNST, or the CA1 region of the hippocampus (HIPPO) on social inter-
action behaviors during withdrawal from chronic ethanol. The CRF dose
(0.5 g), which sensitized ethanol withdrawal-induced anxiety after in-
jection into CeA (Fig. 2) and other sites (Fig. 4), was microinjected twice
at weekly intervals into the PVN, v-BNST, or the CA1 of the HIPPO
before exposure to 5 days of 4.5% ED (see Fig. 1 for protocol). In the
CD-vehicle and the ED-vehicle groups, vehicle was administered into
each of the brain sites (n  3 or 4/site). Because a significant change was
not observed across sites, the data for the sites were combined. No
significant effect on social interaction (P  0.05) was observed during
ethanol withdrawal when the CD-vehicle group was compared with the
ED-vehicle group. A representation of brain region site at which CRF
injections were aimed for each of these brain sites is presented in Sup-
plemental Material. Social interaction was measured 5 to 6 h after the
ethanol diet removal. The number of rats for each group is listed in Table
1, part 3. None of the CRF treatments caused a significant change in
social interaction [F(4,40)  1.487, P  0.05].
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interaction upon ethanol withdrawal. To confirm that this
anxiogenic-like effect of stress before ethanol was mediated
by CRF at CRF-positive brain sites, the CRF-1 receptor an-
tagonist SSR125543 (10 g/l) was microinjected into the
CeA, DRN, or the d-BNST 15 min before the initiation of each
of the 60-min restraint stresses. As shown in Fig. 8, the
anxiogenic effect of ethanol withdrawal from the stress/with-
drawal protocol was completely blocked by the CRF-1 recep-
tor antagonist at each of the brain sites. Previous work has
demonstrated that a CRF-1 receptor antagonist given before
ethanol has no effect on social interaction during withdrawal
from 5 days of ethanol diet (Overstreet et al., 2004). In
agreement with results from other treatments, the locomo-
tion, body weight, and alcohol intake for the groups were not
significantly affected by treatments (Table 1, part 6).
Discussion
Ballenger and Post (1978) hypothesized that multiple de-
toxifications worsen symptoms of withdrawal. In support of
this hypothesis, animal studies demonstrated that repeated
withdrawals from chronic ethanol increase seizure suscepti-
bility (McCown and Breese, 1990) and sensitize withdrawal-
induced anxiety-like behavior (Overstreet et al., 2002). Sub-
sequently, Overstreet et al. (2007) reported that CRF-1
receptor antagonist administration before the first and sec-
ond withdrawals of the multiple withdrawal protocol pre-
vented sensitization of anxiety-like behavior by this protocol,
an observation implicating CRF in the worsening symptoms
of ethanol withdrawal from chronic exposure. Based on a
relationship of CRF to stress, it was reported that repeat
stresses given before a single 5-day exposure to ethanol diet
(stress/withdrawal protocol) substituted for repeated with-
drawals to sensitize anxiety-like behavior (“anxiety”) during
withdrawal from a single 5-day exposure to chronic ethanol
exposure that alone was without effect (Breese et al., 2004).
To assess whether the stress-induced sensitization of with-
drawal-induced anxiety was related to a central action of
CRF, CRF was repeatedly administered intracerebroven-
tricularly to substitute for the stress exposure before the 5
days of ethanol diet (Overstreet et al., 2004). This repeated
intracerebroventricular CRF administration sensitized with-
drawal-induced anxiety—a finding suggesting that stress in-
volves a central, not a peripheral mechanism, to induce this
emotional change during ethanol withdrawal (Overstreet et
al., 2004). This conclusion is consistent with the finding that
repeated peripheral administration of a glucocorticoid before
chronic ethanol exposure does not sensitize withdrawal-in-
duced anxiety (Breese et al., 2004).
The concept that a cumulative adaptation induced by the
repeated chronic ethanol exposures was responsible for the
negative consequences during withdrawal was initially pro-
posed by Koob (2003) to be a change in allostasis—a concept
consistent with that proposed by Ballenger and Post (1978).

















































Fig. 6. CRF-1 receptor antagonist blockade of CRF-induced sensitization of ethanol withdrawal-induced anxiety-like behavior from the central
amygdala, dorsal raphe, and d-BNST. A 10 mg/kg dose of the CRF-1 receptor antagonist, SSR125543 (SSR), was administered intraperitoneally 15
min before the microinjection of CRF (0.5 g) into either the central amygdala or the d-BNST followed by the 5 days of ethanol diet. Meanwhile,
another CRF-1 receptor antagonist CP154526 (CP; 10 mg/kg i.p.) was administered 15 min before each of the CRF (0.5 g) microinjections into the
dorsal raphe. See Fig. 1 for protocol. The action of CRF in these brain sites to induce sensitization of withdrawal-induced anxiety-like behavior was
prevented by the CRF-1 receptor antagonist. Social interaction was measured 5 to 6 h after the ethanol diet removal. The number of rats for each group
is listed in Table 1, part 4. In the CD-vehicle group and the ED-vehicle group, vehicle was administered into each of the brain sites (n  4–6 for each
site), and data were combined because a significant change across sites was not observed. No significant difference in social interaction during ethanol
withdrawal (P  0.05) was observed when the CD-vehicle group was compared with the ED-vehicle group. A representation of brain region at which
CRF injections were aimed for each brain site is presented in Supplemental Material. , P  0.01 compared with vehicle CD- and vehicle ED-treated
groups and the groups that received the SSR125543 systemically [F(7,76)  3.005, P  0.01].
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tion before the first and second withdrawals of the multiple
withdrawal protocols prevented sensitization of withdrawal-
induced anxiety was consistent with this concept (Overstreet
et al., 2004). In the present investigation a CRF-1 receptor
antagonist administered before each of the stress and CRF
applications also prevented sensitization of withdrawal-in-
duced anxiety-like behavior. These findings are consistent
with the idea that both CRF and stress promote a cumulative
adaptive mechanism that affects the subsequent magnitude
of ethanol withdrawal—an adaptation that can also enhance
the negative affect induced by a future stress during absti-
nence from ethanol (Valdez et al., 2003; Breese et al.,
2005a,b,c).
Because others demonstrated that CRF administered into
the CeA was related to the anxiety-like behavior seen during
ethanol withdrawal (Baldwin et al., 1991; Rassnick et al.,
1993), it was next considered whether this or other regions of
brain were involved in the cumulative adaptation by stress
and CRF that supported sensitization of ethanol withdrawal-
induced anxiety-like behavior. When microinjected into the
CeA, CRF, as expected, induced a dose-related sensitization
of withdrawal-induced anxiety. Furthermore, repeated CRF
administrations into the BLA had a sensitizing effect similar
to that for CRF microinjection into the CeA (Figs. 2 and 4).
Collectively, the positive action of repeated CRF administra-
tions into these differing components of the amygdala to
induce sensitization of anxiety during ethanol withdrawal
clearly demonstrates the probable importance of CRF recep-
tors in the amygdala in the cumulative adaptation associated
with the repeated stress/withdrawal protocol sensitization of
symptoms during ethanol withdrawal. Based on these find-
ings in the amygdala, additional brain sites were investi-
gated for CRF-induced sensitization of ethanol withdrawal-
induced anxiety. Repeated CRF exposure of the DRN
likewise sensitized withdrawal-induced anxiety-like behav-
ior. Because the BNST has been overlooked in evaluations of
























































Fig. 8. Microinjection of CRF-1 receptor antagonist (SSR) into the CeA, DRN, or d-BNST before restraint stress prevents sensitization of ethanol
withdrawal-induced anxiety-like behavior. The CRF-1 receptor antagonist SSR125543 (SSR; 10 g/0.5 l) was microinjected into the CeA, DRN, or
the d-BNST 15 min before the two weekly 60-min restraint stresses before exposure to 5 days of 4.5% ED (see Fig. 1 for protocol). Social interaction
was measured 5 to 6 h after the ethanol diet removal. The anxiogenic effect of stress on ethanol withdrawal-induced anxiety was blocked by the
SSR125543 microinjected in the selected brain sites. The number of rats for each group is listed in Table 1, part 6. For the CD-vehicle and ED-vehicle
groups, vehicle was administered into each of the brain sites (n  3–6 for each site). The vehicle data for each of these controls were combined because
a significant change across sites was not observed. No significant effect on social interaction (P  0.05) was observed during ethanol withdrawal when
the CD-vehicle group was compared with the ED-vehicle group. A representation of brain site at which CRF injections were aimed for each site is
presented in Supplemental Material. , P  0.001 compared with the CD-vehicle, ED-vehicle, and CD stress groups as well as the groups that received









































Fig. 7. Repeated UCN-3 microinjected intracerebroventricularly, or into
the central amygdala or the dorsal raphe, before ethanol diet was without
effect on social interaction during withdrawal from chronic ethanol. The
UCN-3 dose (0.5 g/0.5 l) was microinjected twice at weekly intervals
into the CeA, DRN, or the d-BNST before exposure to 5 days of 4.5% ED
(see Fig. 1). Meanwhile, UCN-3 (5 g/5 l) was microinjected intracere-
broventricularly in another group. Social interaction was measured 5 to
6 h after the ethanol diet removal. In ED-vehicle group, vehicle was
administered into each of the brain sites (n  4–6 for each site), and data
were combined because a significant change across sites was not ob-
served. No significant difference in social interaction during ethanol
withdrawal (P  0.05) was observed when the CD-vehicle group was
compared with the ED-vehicle group. No significant difference on social
interaction was observed during ethanol withdrawal between rats that
received UCN-3 or the ones that received vehicle injections (ED vehicle
and CD vehicle). UCN-3 by itself did not induce anxiety either (CD UCN
3). [F(6,59)  1.838, P  0.05]. The n for each group is listed in Table 1,
part 5.
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both the dorsal and ventral components of the BNST (Egli
and Winder, 2003) were individually microinjected with
CRF. Consistent with previous work showing that CRF in-
duces anxiety-like behavior when microinjected into this site
(Sahuque et al., 2006), repeated CRF microinjection into the
d-BNST before ethanol diet sensitized withdrawal-induced
anxiety (Fig. 4), although CRF administered into the v-BNST
did not (Fig. 5). Collectively, these data indicate that CRF is
capable of acting within several regions of the brain to
sensitize withdrawal-induced anxiety-like behavior. Con-
sequently, in contrast to other investigations, the focus of
the present study provided an unexpected outcome in that
several brain sites injected with CRF supported equally
the degree to which an adaptive action resulted in sensi-
tization of withdrawal-induced anxiety-like behavior. The
relevance and neural basis of several sites being equally
effective for CRF to induce sensitization of ethanol with-
drawal-induced anxiety will need clarification in future
experiments.
Despite CRF presence in the hippocampus and the PVN,
microinjection of CRF into these sites did not support the
CRF-induced sensitization of withdrawal-induced anxiety
(Fig. 5). A sensitization by CRF into the PVN might not have
been expected, because repeated administration of corticoste-
rone does not substitute for repeated stresses to sensitize
withdrawal-induced anxiety (Breese et al., 2004). However,
this finding also suggests that any action of CRF in the PVN
by stress does not activate other brain regions that support
the stress-induced anxiety-like behavior that follows ethanol
withdrawal. Despite evidence that CA1 hippocampal pyrami-
dal cells have been investigated extensively with respect to
plasticity changes by stress (McEwen, 2001) and chronic
ethanol (Liang et al., 2006), repeated CRF into this brain site
did not support sensitization of withdrawal-induced anxiety.
Therefore, the plasticity of this brain site associated with
chronic ethanol and stress probably supports other functions
not associated with the adaptation that results in sensitiza-
tion of anxiety during ethanol withdrawal (e.g., depressive-
like behavior).
To confirm that the sensitization of ethanol withdrawal-
induced anxiety by the repeated CRF exposures was related
to activation of a specific CRF-receptor subtype, two ap-
proaches were undertaken (Figs. 6 and 7). First, systemic
administration of a CRF-1 receptor antagonist before re-
peated CRF microinjection into the CeA, the DRN, or the
d-BNST was capable of preventing the CRF-induced sensiti-
zation of anxiety. In further support of the repeated CRF
acting on CRF-1 and not CRF-2 receptors to induce sensiti-
zation, UCN-3, an endogenous agonist specific for CRF-2
receptors (Lewis et al., 2001), did not sensitize withdrawal-
induced anxiety when microinjected into the CeA, DRN, and
d-BNST, the three brain sites associated with CRF-induced
sensitization of anxiety during ethanol withdrawal. In addi-
tion, UCN-3, when injected intracerebroventricularly, did
not elicit ethanol withdrawal-induced anxiety either. Collec-
tively these results indicate that CRF-2 receptor activation in
the CeA, DRN, or d-BNST is not responsible for the CRF-
induced sensitization of anxiety during ethanol withdrawal.
Likewise, because intracerebroventricular administration of
UCN-3 was without effect, CRF-2 receptors from other brain
regions do not seem to be involved in the stress sensitization
either.
To define whether CRF release at the CeA, DRN, or
d-BNST sites was activated by the repeated stress/with-
drawal protocol to induce sensitization of withdrawal-in-
duced anxiety, the CRF-1 receptor antagonist SSR 125543
was microinjected into each of these sites before each stress
(Fig. 8). The anxiogenic response during ethanol withdrawal
from repeated stresses was completely blocked by the CRF-1
receptor antagonist microinjected into each of these brain
sites, a finding that strongly supports the stress/withdrawal
protocol inducing anxiety through activation of CRF-1 recep-
tors in the CeA, DRN, or d-BNST. Thus, these results are
consistent with CRF-1 receptors being the primary target for
sensitization of anxiety during withdrawal from ethanol in-
duced by the CRF/withdrawal and stress/withdrawal proto-
cols (Breese et al., 2004; Overstreet et al., 2004).
The tension-reduction hypothesis of alcoholism was pub-
lished several decades ago to suggest that the consequence of
stress per se increased alcohol drinking (Conger, 1956); how-
ever, more recent studies (Breese et al., 2004; Overstreet et
al., 2007) raised the possibility that adaptation induced by
stresses before a bout of alcohol abuse can also contribute to
adaptive change much as repeated exposures to ethanol (Bal-
lenger and Post, 1978; Overstreet et al., 2002). Bale and Vale
(2004) have reviewed the evidence for CRF involvement in
stress. The present effort provides evidence that stress expo-
sure before ethanol depends on release of CRF onto CRF-1
receptors in specific brain sites that are capable of facilitat-
ing adaptive change induced by a lesser amount of etha-
nol—a change that results in a negative outcome during
withdrawal from chronic ethanol (Breese et al., 2004,
2005a,b,c; Overstreet et al., 2004). In this respect, previous
work has provided support for the conclusion that CRF con-
tributes to adaptive change related to persistent alcohol ex-
posure (Overstreet et al., 2004; Heilig and Koob, 2007). Fur-
thermore, basic data (Breese et al., 2005a,b) indicate that
stress after chronic ethanol can precipitate negative affect, a
response which one could speculate is comparable with the
negative affect observed in the abstinent alcoholic that re-
sults in craving (Sinha, 2001; 2008; Sinha et al., 2009). Both
basic (Breese et al., 2005a,b) and clinical findings (Heilig et
al., 2007) indicate that a CRF-1 receptor antagonist will
prevent the negative consequences of stress after chronic
ethanol exposure. Future investigations will be required to
address whether chronic treatment of alcoholics adminis-
tered a CRF-1 receptor antagonist could be a successful ap-
proach to minimize the increased susceptibility alcoholics
display for increased craving to stress (Sinha, 2001; Yoon et
al., 2006; Sinha et al., 2009).
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